Cytokinetics, Incorporated (CYTK)
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM
Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart ​condition that currently has no approved treatments.
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics Q2 Earnings Call Highlights
Cytokinetics NASDAQ: CYTK reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM.
